Back to Search Start Over

Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma

Authors :
Conchita Vens
Paul B. Essers
Marcel Verheij
C. René Leemans
Michiel W. M. van den Brekel
David M. Vossen
Harry Bartelink
Ruud H. Brakenhoff
Martijn van der Heijden
Reinout H. de Roest
Otolaryngology / Head & Neck Surgery
CCA - Imaging and biomarkers
Graduate School
Oral and Maxillofacial Surgery
Maxillofacial Surgery (AMC)
Source :
Essers, P B M, van der Heijden, M, Vossen, D, de Roest, R H, Leemans, C R, Brakenhoff, R H, van den Brekel, M W M, Bartelink, H, Verheij, M & Vens, C 2020, ' Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma ', International Journal of Cancer, vol. 147, no. 6, pp. 1732-1739 . https://doi.org/10.1002/ijc.32962, International Journal of Cancer, International Journal of Cancer, 147(6), 1732-1739. Wiley-Liss Inc., International journal of cancer. Journal international du cancer, 147(6), 1732-1739. Wiley-Liss Inc., International Journal of Cancer, 147(6), 1732-1739. International Union Against Cancer
Publication Year :
2020

Abstract

DNA copy number alterations (CNAs) are frequent in cancer, and recently developed CNA signatures revealed their value in molecular tumor stratification for patient prognosis and platinum resistance prediction in ovarian cancer. Head and neck squamous cell carcinoma (HNSCC) is also characterized by high CNAs. In this study, we determined CNA in 173 human papilloma virus‐negative HNSCC from a Dutch multicenter cohort by low‐coverage whole genome sequencing and tested the prognostic value of seven cancer‐derived CNA signatures for these cisplatin‐ and radiotherapy‐treated patients. We find that a high CNA signature 1 (s1) score is associated with low values for all other signatures and better patient outcomes in the Dutch cohorts and The Cancer Genome Atlas HNSCC data set. High s5 and s7 scores are associated with increased distant metastasis rates and high s6 scores with poor overall survival. High cumulative cisplatin doses result in improved outcomes in chemoradiotherapy‐treated HNSCC patients. Here we find that tumors high in s1 or low in s6 are most responsive to a change in cisplatin dose. High s5 values, however, significantly increase the risk for metastasis in patients with low cumulative cisplatin doses. Together this suggests that the processes causing these CNA signatures affect cisplatin response in HNSCC. In conclusion, CNA signatures derived from a different cancer type were prognostic and associated with cisplatin response in HNSCC, suggesting they represent underlying molecular processes that define patient outcome.<br />What's new? DNA copy number alterations (CNA) reflect the involvement of crucial mutational processes in cancer and has the potential to inform tumor molecular stratification for precision medicine. While CNA signatures have been developed in ovarian cancer, their application in other cancers remains elusive. Here, the authors demonstrate the applicability of ovarian cancer CNA signatures in head and neck squamous cell carcinoma (HNSCC), which is also characterized by high CNA numbers, treated with radiotherapy and cisplatin. Several of the CNA signatures exhibited a prognostic role in two independent HNSCC cohorts that was dependent on cisplatin treatment and the anatomical subsite.

Details

Language :
English
ISSN :
00207136
Database :
OpenAIRE
Journal :
Essers, P B M, van der Heijden, M, Vossen, D, de Roest, R H, Leemans, C R, Brakenhoff, R H, van den Brekel, M W M, Bartelink, H, Verheij, M & Vens, C 2020, ' Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma ', International Journal of Cancer, vol. 147, no. 6, pp. 1732-1739 . https://doi.org/10.1002/ijc.32962, International Journal of Cancer, International Journal of Cancer, 147(6), 1732-1739. Wiley-Liss Inc., International journal of cancer. Journal international du cancer, 147(6), 1732-1739. Wiley-Liss Inc., International Journal of Cancer, 147(6), 1732-1739. International Union Against Cancer
Accession number :
edsair.doi.dedup.....a28d639c12b483f64b396c4244ad4673
Full Text :
https://doi.org/10.1002/ijc.32962